ABBV-744 is a selective inhibitor of Bcl-2 family proteins, particularly Bcl-xL, designed to promote cancer cell death by restoring apoptosis in tumor cells. It is primarily investigated for its potential in treating solid tumors and hematologic malignancies where Bcl-xL overexpression contributes to cancer cell survival and resistance to therapy. Due to its selectivity, ABBV-744 aims to reduce the thrombocytopenia commonly associated with dual Bcl-2/Bcl-xL inhibitors, potentially allowing for higher therapeutic doses with improved safety. It is being studied in preclinical and clinical settings, often in combination with other anticancer agents such as chemotherapy or targeted therapies, to enhance treatment efficacy in cancers like small cell lung cancer, prostate cancer, and multiple myeloma.